Budget impact analysis of the incorporating of biosimilars in a cancer institute of a philanthropic hospital
Objective: Global healthcare costs continue to rise annually, and this is a major challenge given the scarce resources and growing prices of innovative drugs. An interesting alternative for reducing costs is the use of biosimilars. This study aimed to assess the financial impact of introducing biosi...
Saved in:
Main Authors: | Maria Luísa BRODT-LEMES (Author), Diana Saiara BRUSCATO (Author), Douglas Silva MADRUGA (Author), Joice SMANIOTTO (Author), Julia Roberta SAGGIORATO-LUBIAN (Author), Letícia Tramontina DE-VILLA (Author), Suhélen CAON (Author), Thamyrys Bessa SILVA (Author) |
---|---|
Format: | Book |
Published: |
Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Femmes philanthropes
by: Yolande Cohen
Published: (2010) -
Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019
by: Manuel García-Goñi, et al.
Published: (2021) -
Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
by: Yujeong Kim, et al.
Published: (2020) -
The increase of philanthropic entities in the SUS: what does this scenario reveal?
by: João Felipe Marques da Silva, et al.
Published: (2023) -
Smart money? Philanthropic and federal funding for the Common Core
by: Mindy L. Kornhaber, et al.
Published: (2016)